Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to learn about how Pristiq is currently being used in general practice and how psychiatrists and primary care physicians currently perceive Pristiq in terms of efficacy, tolerability, and adherence compared to other treatments for major depressive disorder (MDD).

Detailed Description
-----------------
It is retrospective patient chart study among psychiatrists and primary care physicians (PCPs) treating patients suffering from major depressive disorder (MDD). Physicians will be asked general medical questions in order to quantify their prescribing behavior and their perception of treatment performance. A retrospective patient chart review will then be performed and patient data will be collected to document patient characteristics and actual treatment outcomes. Upon qualification, specific instructions for chart review will be provided. Once the identified charts are pulled, the physicians are instructed to continue with the on-line survey. In total, there will be approximately 450 psychiatrists and 450 primary care physicians participating in this trial.

Official Title
-----------------
A Retrospective Study To Evaluate The Current Utilization Of Desvenlafaxine Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Other: Pristiq first-line treatment charts
* Other: Pristiq second-line treatment charts
* Other: SNRI or SSRI first-line treatment charts
* Other: SNRI or SSRI second-line treatment charts


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be adult, diagnosed with major depressive disorder and treated with pharmacotherapy. Physicians must be either a psychiatrist or a primary care physician, a prescriber of Pristiq, have at least 3 charts representing the 4 identified patient types, have been in clinical practice between 4 and 35 years, primarily office based (50%+), not participated in a research study relating to antidepressants or antidepressant therapy within the past month, not a consultant or have a professional relationship with a pharmaceutical company other than for clinical trials or speaking engagements, and not be employed by of affiliated with an advertising agency, market research company, or pharmaceutical company. Exclusion Criteria: Patients who have not been treated for depression.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients initiated on Pristiq as a first line treatment<br> | Other: Pristiq first-line treatment charts<br>* 300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment<br>|
| Patients initiated on Pristiq as a 2nd-line treatment<br> | Other: Pristiq second-line treatment charts<br>* 800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).<br>|
| Patients initiated on a SNRI or SSRI as a first-line treatment<br> | Other: SNRI or SSRI first-line treatment charts<br>* 800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.<br>|
| Patients initiated on a SNRI or SSRI as a 2nd-line treatment<br> | Other: SNRI or SSRI second-line treatment charts<br>* 800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment. |  | 6 months | 
| 800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a SNRI or SSRI). |  | 6 months | 
| 800 charts including patients initiated on a SNRI or SSRI (excluding Pristiq) within the past 6 months as a first-line treatment. |  | 6 months | 
| 800 charts including patients initiated on a SNRI or SSRI (excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI). |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse events and Incidence of discontinuation due to adverse events |  | 6 months | 
| Percent of patients experiencing relapse |  | 6 months | 
| Length of time to relapse |  | 6 months | 
| Percent of discontinuation / medication switches due to lack of efficacy |  | 6 months | 
| Subjective physician assessment of symptom control |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
retrospective chart review study, desvenlafaxine utilization, psychiatrists and primary care physicians, treatment of major depressive disorder